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Abstract 
Purpose: To investigate the anti-cancer activities of C5 extract (C5E), a new herbal preparation from 
Korea, on B16F10 cells. 
Methods: The anti-proliferative effects of C5E were assessed by culturing B16F10 cells in the presence 
or absence of C5E. Cell cycle progression was analyzed by PI staining using flow cytometry. The 
quantities of apoptosis-inducing proteins were measured by Western blot. 
Results: C5E inhibited the proliferation of B16F10 cells but not human keratinocytes. C5E induced S 
phase arrest by interfering with cell regulatory factors such as cyclins B1, D1, D3, and E, and cyclin-
dependent kinase 2, in B16F10 cells. Furthermore, immunoblot analysis confirmed that treatment with 
C5E induced apoptosis and cleaved caspase-3, poly (ADP-ribose) polymerase, via extrinsic pathway, 
whereas Bcl-2 expression was down-regulated. In addition, the suppression of cell proliferation by C5E 
is through down-regulation of p-Akt, up-regulation of phosphatase and tensin homolog protein 
expression via phosphoinositol 3 kinase survival signaling pathways in B16F10 cells. The combined 
cytotoxic effects of C5E and vinblastine generated 10 % increase in activity in contrast to the sum of the 
inhibitory effects of the individual agents. 
Conclusion: C5E shows promising anti-cancer activity and can be a useful adjuvant with vinblastine in 
combination therapeutic treatment of skin cancer. 
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Metastasis, invasion, angiogenesis, and 
uncontrolled growth are characteristics of cancer. 
Cancer is a fatal disease that requires a 
multipronged therapeutic approach. Chinese 
herbal medicines exert multiple effects to inhibit 
metastasis, angiogenesis, and tumor growth [1]. 
Herbal medicines are generally abundant with 
low cost, and relatively non-toxic, and plant 
extracts are thought to be therapeutically 
superior to anti-cancer drugs in some cases 
[2,3]. Apoptosis is an important mode of 
programmed cell death, which is very different 
from necrosis [4]. Apoptotic cells undergo 
characteristic changes such as chromatin 
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condensation, nuclear fragmentation, and 
blebbing [5].  
 
To prevent tumorigenesis, it is very important to 
eliminate abnormal cells by apoptosis at early 
stage. Apoptosis is regulated by either the 
extrinsic or the intrinsic apoptotic pathway [6,7]. 
The extrinsic pathway involves caspase-8 
activation leading to the activation of downstream 
effectors caspases-3 and poly (ADP-ribose) 
polymerase (PARP) [8]. On the other hand, the 
intrinsic pathway depends on stress signals from 
within the cells, leading to the activation of 
caspase-9 through the release of mitochondrial 
factors, and then causing the activation of 
caspase-3 and PARP [9,10]. However, cancer 
cells, especially metastatic cancer cells, are 
commonly resistant to both apoptotic pathways. 
Thus, agents that can induce apoptosis in cancer 
cells would be effective for cancer treatment [11]. 
The phosphoinositol 3 kinase (PI3K)/Akt/ 
mammalian target of rapamycin (mTOR) 
pathways are important signaling pathways 
regulating cell growth, survival, and motility in 
cancer cells [12]. PI3K is mutated in many 
cancers and these mutations cause the kinase to 
be more active [13,14]. Akt is involved in the 
nuclear factor kappa B (NF-kB) signaling 
pathway mediated through inhibitor of kappa B 
(IkB) kinase (IKK) regulation. [15]. mTOR has 
been identified as a downstream target of both 
the PI3K [16,17] and Ras [18,19] signaling 
pathways. Chemotherapy is one of the primary 
therapeutic approaches used to treat cancer 
patients. However, in many cases, chemotherapy 
alone cannot achieve satisfactory effects, and it 
causes severe side effects at effective doses. 
 
Vinblastine is an anti-microtubule drug used to 
treat certain kinds of cancer. Vinblastine was first 
used in 1958 to treat Hodgkin’s lymphoma; 
vincristine was introduced in 1962 [20]. 
Vinblastine is one of the most effective cytotoxic 
agents for the treatment of a variety of solid 
malignant tumors such as melanoma. Despite its 
excellent anti-cancer activity, the clinical use of 
vinblastine is often limited by its undesirable side 
effects, such as severe neuropathies and 
hepatotoxicity [21,22]. 
 
In this study, we investigated the inhibitory effect 
of C5 extract (C5E) on the proliferation of 
B16F10 cells, its ability to induce apoptosis via 
both the extrinsic and intrinsic pathways, and its 
effect on PI3K/Akt/mTOR survival signaling 
pathways. Its influence on cell cycle progression 
and its combined cytotoxic effects with 




Plant materials and methods of extraction 
 
Herbal ingredients were obtained from the 
Oriental Medical Hospital, Dongguk University 
(Ilsan, Korea) and kindly authenticated by Dr. 
Seong Hyun Jeong (Department of Oriental 
Herbal Materials, Dongguk University). This 
formula consists of 10 Oriental medicinal herbs 
(Table 1). 
 




name    
Country 
of origin Grams % 
Ginseng Korea 166 16.6 
Chaga Russia 166 16.6 
Pinellia Tuber China 111 11.1 
Sparganium Rhizome China 56 5.6 
Alpinia Rhizome China 56 5.6 
Cinnamon Bark Vietnam 56 5.6 
Astragalus Root Korea 56 5.6 
Psoraleae Semen India 111 11.1 
Evodiae Fruit China 111 11.1 
Meliae Fructus   China 111  11.1 
   Total   1000  100 
 
This was formulated for use in cancer patients. 
The 10 ingredients and their proportions (w/w) 
were as follows: Ginseng, Korea, 16.6 %; Chaga, 
China, 16.6 %; Pinellia Tuber, China, 11.1 %; 
Sparganium Rhizome, China, 5.6 %; Alpinia 
Rhizome, China, 5.2 %; Cinnamon Bark, 
Vietnam, 5.2 %; Astragalus Root, Korea, 5.6 %; 
Psoraleae Semen, India 11.1 %; Evodia Fruit, 
China, 11.1 %; Meliae Fructus, China, 11.1 % 
 
Extraction of C5E and constituent herbs  
 
The ethanol extract was prepared as follows: The 
dried and pulverized medicinal herbs were mixed 
together and a 1-kg batch was soaked with 40 % 
ethanol (3 liters). The ethanol extract was 
concentrated using a rotary evaporator, 
lyophilized, and reconstituted in dimethysulfoxide 




Human melanoma A375, murine melanoma 
B16F10, and human small lung NCI-H1299 p53 
(-/-) cancer cells, and the human normal 
keratinocyte cell line HaCaT, were purchased 
from the American Type Culture Collection 
(ATCC, Manassas, VA). B16F10, HaCaT, and 
NCI-H1299 p53 (-/-) cells were grown in 
Dulbecco’s modified Eagle medium (DMEM) and 
in RPMI 1640 medium supplemented with 10 % 
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heated inactivated fetal bovine serum, 100 
units/mL of penicillin, and 100 μg/mL of 
streptomycin in a humidified atmosphere 




The anti-proliferative effect of C5E on A375, 
B16F10, and NCI-H1299 p53 (-/-) cells and 
HaCaT cells was determined using the Cell 
Counting Kit (CCK)-8 (Dojindo Laboratories, 
Kumamoto, Japan), according to the 
manufacturer’s instructions. All cells (1 × 
104/well) were incubated in 96-well plates. 
Subsequently, the cells were treated with various 
concentrations of C5E (50, 100, 200, and 400 
μg/mL) for 24 and 48 h. To examine the 
combined effects with vinblastine sulfate, 
B16F10 cells were treated with various 
concentrations of C5E (50, 100, 200 and 400 
μg/mL) and vinblastine (0, 0.125, 0.25, 0.5, 55, 
110 nM) for 24 and 48 h. CCK-8 (10 μl) was 
added to each well, and the cells were incubated 
for 3 h. The absorbance was measured at 450 
nm using a microplate reader and the completed 
medium was used as the blank. Cytotoxicity in 
the C5E-treated culture was expressed as 
follows: 
 
Death (%) = (C5/Cm)100 …………………... (1) 
 
Where C5 and Cm are the absorbance of C5E- 
and Cm-treated cells, respectively. 
 
Morphological examination by 
immunofluorescence microscopy 
 
B16F10 cells were seeded on sterilized 
coverslips in 24-well plates (0.5 × 104cells/well), 
incubated overnight, and then treated with 
various concentrations of C5E. After 24 h, the 
cells on the coverslip were washed twice with 
serum-free medium, fixed, and permeabilized 
with cold acetone on ice for 10 min. The 
coverslips were washed with phosphate-buffered 
saline (PBS) 3 times and blocked with 0.1 % 
bovine serum albumin (BSA) in PBS at room 
temperature for 30 min. 
 
The primary antibody (against cleaved caspase 
7; Cat. Sc-8008; Santa Cruz Biotechnology, 
Santa Cruz, CA) was diluted (1:100) in 0.1 % 
BSA in PBS and added to the coverslip at 4 °C 
overnight. After washing with PBS 3 times, the 
coverslip was incubated with the secondary 
antibody (fluorescein isothiocyanate [FITC]-
conjugated goat anti-mouse IgG) diluted (1:400) 
in 0.1 % BSA in PBS for 1 h. The slide was then 
washed 3 times with PBS, exposed to 4', 6-
diamidino-2-phenylindole (DAPI; 1:1,000) for 10 
s, and washed with PBS twice. The stained cells 
were visualized using an uplight fluorescence 
microscope (Olympus, Tokyo, Japan). 
 
Analysis of cell cycle distribution and 
apoptosis 
 
To examine cell cycle progression, B16F10 cells 
(2.5 × 105cells per 6-well plate) were treated with 
various concentrations of C5E (0, 0.2, and 0.4 
mg/ml) and vinblastine (55 nM) for 24 h. To 
examine the phase distribution of the DNA 
content of the cells, propidium iodide (PI; Sigma, 
St. Louis, MO) staining was performed. After 
treatment, the cells were harvested and fixed in 
70 % ethanol. The fixed cells were washed with 
PBS, incubated with RNase A (5 mg/ml) for 30 
min, stained with PI (1 mg/ml) for 5 min at room 
temperature in the dark. To determine the 
apoptosis induced by C5E in B1610 melanoma 
cells, annexin V staining (BD Bioscience, San 
Jose, CA) was performed according to the 
manufacturer’s instructions. B16F10 cells (2.5 × 
105cells per 6-well plates) were treated with 
various concentrations of C5E (0, 200, and 400 
μg/mL) and co-treated with vinblastine (55 nM) 
for 24 h, and subsequently labeled with 10 μg/mL 
PI and annexin V-FITC. Apoptosis and cell cycle 
distribution of C5E-treated B16F10 melanoma 
cells were assessed using a BD FACSCalibur 
flow cytometer (BD Biosciences) using CellQuest 
Software. The percentages of cells in different 
phases of the cell cycle were analyzed using the 
WinMDI Version 2.9 program (Copyright. 
1993~2000; Joseph Trotter). 
 
Western blot analysis 
 
B16F10 cells (2.5 × 105/mL) were plated in each 
60-mm culture dish prior to drug treatment. After 
24 h of cell attachment, cells were treated with 
either growth medium alone, as control, or with 
varying concentrations of C5E (0, 200, and 400 
μg/mL) and co-treated with vinblastine (55 nM) 
for 24 h. At the end of the treatment, cells were 
lysed and protein concentrations were 
determined by the Bio-Rad protein assay kit 
(Pierce, Rockford, IL) with albumin as the 
standard. All samples (30–40 μg of proteins) 
were subjected to 12 % sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
The proteins in the gels were then transferred to 
nitrocellulose membranes. After blocking the 
membranes with 5 % non-fat milk, the 
membranes were then incubated with antibodies 
against p-Akt, Akt, cyclin B1, cyclin D1, cyclin 
D3, cyclin E, p-p53, p53, PARP, cleaved 
caspase-3, p27, p21, Bax, Bcl-2, and 
glyceraldehyde phosphate dehydrogenase 
(GAPDH) at 4 °C overnight. The membranes 
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were washed 3 times in PBST (10 mM NaH2PO4, 
130 mM NaCl, 0.05 % Tween 20), and then 
probed with secondary antibodies (horseradish 
peroxidase-conjugated anti-rabbit and anti-
mouse antibodies; 1:2000 in blocking solution) 
for 1 h. After washing with PBST 3 times, 
enzyme activity on the blot was visualized 
through chemiluminescence by adding ECL 




The results were pooled from 3 independent 
experiments. Data from the cell viability assay 
and flow cytometric analyses are expressed as 
mean ± standard error of the mean (SEM) and 
analysis of variance (ANOVA) followed by 
Tukey’s test and Dunnet’s test performed on 
GraphPad Prism 5 (San Diego, CA) to determine 





The chemical content of C5E 
 
C5E contained Ginseng (Korea, 16.6 %), Chaga 
(China, 16.6 %), Pinellia tuber (China, 11.1 %), 
Sparganium rhizome (China, 5.6 %), Alpinia 
rhizome (China, 5.2 %), Cinnamon bark 
(Vietnam, 5.2 %), Astragalus root (Korea, 5.6 %), 
Psoraleae semen (India 11.1 %), Evodia Fruit 
(China, 11.1 %), and Meliae fructus (China, 11.1 
%). We identified the potential medicinal 
components of the C5E extract using gas 
chromatography mass spectrometry (GC-MS; 
Figure 1). 
 
Compounds were identified by comparison with 
those in the Wiley 6th edition MS spectra library 
(in the library search program, hits that were > 90 
% probable were viewed as likely hits). Table 2 
lists the chemical components of the extract. The 
analysis yielded 1 compound, coumarin, which is 
known to have anti-cancer properties (Figure 1, 
Table 2). 
 
The anti-tumor effects of C5E with vinblastine 
 
We first investigated cytotoxic responses in 
HaCaT cells, NCI-H1299 p53 (-/-) cells, B16F10 
cells, and A375 cells exposed to various 
concentrations of C5E (50, 100, 200, and 400 
μg/mL) for 24 h and 48 h. HaCaT normal 
keratinocytes were not affected by C5E (Figure 
2A). C5E was cytotoxic to B16F10 cells with an 
IC50 value of 0.3 mg/ml after 24-h treatment 
(Figure 2C). Treatment of B16F10 cells for 48 h 
induced more significant cell death compared to 
24-h-treatment at C5E concentrations of 0.1 to 
0.8 mg/ml (Figure 2C); the NCI-H1299 p53 
knockout cells were also affected in a dose-
dependent manner, but to a lesser extent than 
B16F10 cells (Figure 2B). This means that C5E 
may induce cell death by not only a p53-
dependent pathway but also a p53-independent 
pathway in melanoma cells. The other melanoma 
cells, A375, were only slightly inhibited by C5E, 
compared to B16F10 cells (Figure 2D). 
 
 
Figure 1: Composition of C5E was analyzed by GC-MS. Among the volatile compounds in C5E, 1-phenyl-3-
butanone, angelicin and ficusin are major components. Coumarin, which has anti-cancer properties, was also 
identified 
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Figure 2: Dose- and time-dependent effects of C5E on the proliferation of several cell lines. (a) Human 
keratinocyte cells, HaCaT; (b) NCI-H1299, p53 knockout cells; (c) mouse melanoma cells, B16F10; (d) Human 
melanoma cells and A375 cells were treated for 24 h with different concentrations of C5E in the presence or 
absence of 55 nM vinblastine. Cell viability was determined by the CCK-8 assay. The data were normalized to 
the control cells. Data are expressed as the mean ± SD (n = 5). *p < 0.05, **p < 0.001, ***p < 0.0001, compared 
to untreated control 
 
Table 2: Volatile compounds identified in C5E 
 
Compounds Retention time (min) 
Relative 
(%) 
3-Phenylpropanal 19.020 7.41 
3,4-Dimethyl-benzaldehyde 20.701 9.55 
1-Phenyl-3-butanone 21.451 23.53 
Coumarin 26.882 2.65 
Methyldymron 27.755 1.05 
2,4-Di-tert-butylphenol 28.543 0.78 
Coniferyl alcohol 30.120 4.93 
Angelicin 34.881 24.54 
Ficusin 36.060 22.05 
Unknown 41.463 1.89 
Priscoline 44.881 1.61 
 
Vinblastine was used at the optimal dose (55 nM) 
for its anti-cancer effect, as a positive control for 
comparison with the effects of C5E. The results, 
shown in Fig. 2, indicated that C5E inhibited the 
proliferation of A375 cells and B16F10 cells at 
100 µg/ml, reaching a maximum cell death 
percentage of ~75 % and ~48 % in the presence 
of 800 µg/ml (Figure 2C, 2D), but this was not 
seen in normal human keratinocyte HaCaT cells 
and this effect occurred in a concentration-
dependent manner. Figure 2C shows that C5E 
enhances the antitumor efficacy of vinblastine in 
the B16F10 melanoma cell line. Therefore, C5E 
showed strong anti-cancer activity with low 
toxicity to normal cells. To further examine the 
potential anti-cancer effects of C5E, its combined 
inhibitory effect with vinblastine on the 
proliferation of B16F10 cells were investigated. 
The cells were incubated with various doses of 
C5E for 24 h and 48 h with vinblastine (55 nM). 
Vinblastine showed combined inhibitory effects 
with various doses of C5E (0.2, 0.4, and 0.8 
mg/mL) on B16F10 cells, but only slight 
combined inhibitory effects were observed on 
HaCaT, NCI-H1299 (p53-/-), and A375 cells 
(Figure 2). Combined inhibitory effects on cell 
proliferation were observed clearly with 0.2, 0.4, 
and 0.8 mg/ml C5E plus 55 nM vinblastine, 
respectively, compared to C5E alone (Figure 
2C). On the other hand, the NCI-H1299 p53 
knockout cells were affected in a dose-
dependent manner, but to a lesser extent than 
B16F10 cells (Figure 2B). 
 
Apoptosis of B16F10 cells treated with C5E 
 
To investigate the apoptosis-induced effects of 
C5E, B16F10 cells exposed to C5E were  
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Figure 3: Effect of C5E on apoptosis in B16F10 cells. (A, B) B16F10 cells were treated with various 
concentrations of C5E (0.2 and 0.4 mg/ml) in the presence or absence of 55 nM vinblastine for 24 h. Cellular 
apoptosis was measured by flow cytometry using double-staining with FITC-conjugated annexin V and PI. 
Annexin-positive/PI-negative cells have undergone early apoptosis. Annexin-positive/PI-positive cells are in late 
apoptosis. (C) Immunoblot analysis of cleaved PARP, pro-caspase-3, cleaved caspase-3, Bcl-2, and Bax levels 
in cell lysates from C5E- and vinblastine-treated B16F10 cells 
 
analyzed using annexinV-FITC & PI staining on a 
flow cytometer (Becton-Dickinson, Franklin 
Lakes, NJ). Annexin- and PI-negative cells are 
live cells (Q3), and PI single-staining (annexin-
negative) represents necrotic cells (Q2). 
Annexin-positive/PI-negative cells (Q4) are those 
that have undergone early apoptosis, whereas 
annexin- and PI-positive cells (Q1) are late 
apoptotic cells. The control cells were in Q3, 
which indicates that the cells were alive and in 
good condition. In contrast, C5E-treated cells 
appeared in Q1 and Q4, which represent cells 
undergoing apoptosis. Our results demonstrate 
that C5E induces apoptosis in a dose-dependent 
manner. The number of B16F10 cells in the sub-
G1 phase increased significantly after treatment 
with 0.2 and 0.4 mg/mL C5E (Figure 3A, B). 
 
Vinblastine slightly increased the apoptotic effect 
of C5E at 0.2 and 0.4 mg/ml. To confirm these 
results, the effects exerted by C5E on the activity 
of apoptosis-inducing proteins in B16F10 cells 
were studied. C5E increased the activation of 
caspase-3 cleavage and Bax. To further confirm 
these results, we performed immunofluorescence 
to track caspase-7 (Figure 4). 
 
These results suggest that C5E induced 
apoptosis by enhancing the caspase signal 
pathway. 
 
C5E inhibits cell cycle progression and 
modulates cell cycle-related factors 
 
We investigated the effects of C5E on cell cycle 
regulation. Cell cycle progression was measured 
by PI staining with quantitation of DNA content 
using flow cytometry. As shown in Figures 5A 
and 5B, the non-treated cells were mainly 
present in the G0/G1 phase, whereas the C5E-
treated cells cycled into the sub-G1 phase in a 
dose-dependent manner. 
 
To confirm these results, we performed 
immunoblots to analyze cell cycle regulatory 
factors. P53 is involved in the G1/S and G2/M 
phases and is active in the phosphorylated form 
(20). We investigated DNA degradation in a 
dose-dependent manner (Figure 5C). Cell cycle 
regulatory factors such as p53 and p-p53 were 
upregulated by C5E, thereby terminating the cell 
cycle at the G1 phase and preventing cell 
division. Cyclin B1 was downregulated by C5E 
treatment in a dose-dependent manner (Figure 
5C). These results indicate that treatment with 
C5E is capable of inducing apoptosis and 
delaying the cell cycle at the G0/G1 phase in 
B16F10 melanoma cells. 
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Figure 4: Immunofluorescence was performed to measure the amount of cleaved caspase-7 in B16F10 
melanoma cells. B16F10 cells were treated with various concentrations of C5E (0.2 and 0.4 mg/ml) and 
vinblastine (55 nM) for 24 h. Fixed and stained cleaved caspase-7 (green fluorescence), α-tubulin (red 
fluorescence), and nuclei (blue fluorescence) were detected using immunofluorescence confocal microscopy 
 
 
Figure 5: Effects of C5E on cell cycle progression in B16F10 cells. (A) Cell cycle profiles of B16F10 cells treated 
with various concentrations of C5E (0, 0.2, 0.4 mg/ml) in the presence or absence of 55 nM vinblastine for 24 h. 
(B) The proportions of the population in the different cell cycle phases, quantified from the profiles, are 
represented in the bar graphs along with the SEM of 3 independent experiments. *p < 0.05, **p < 0.001, ***p < 
0.0001, compared to untreated control. (C) Immunoblots of cell cycle regulatory factors. GAPDH was used as an 
internal control 
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C5E downregulates expression of MAPKs, 




Figure 6: Effect of C5E on the expression of survival 
signaling factors in B16F10 cells. B16F10 cells were 
treated with various concentrations of C5E (0, 0.2, and 
0.4 mg/ml) in the presence or absence of 55 nM 
vinblastine for 24 h. (A) p38 and p-44/42 MAPK were 
detected by Immunoblot analysis. (B) The expression 
of p-IkB-α and p-AKT were detected by immunoblot 
analysis (C). p-mTOR was detected by immunoblot 
analysis 
 
To further study the effects of C5E on cell 
proliferation, protein expression levels of 
members of the MAPKs, PI3K/Akt, and mTOR 
signaling pathways were investigated. pMAPK, 
p-IkB-a, p-Akt, p-mTOR, and mTOR were 
downregulated by C5E as expected (Figure 6 A, 
B, C). However, p-38 and Akt were not 




C5E is a herbal composition designed to cure 
cancer in a herbal clinic. This herb extract has 
long been used as an anti-cancer agent at the 
Oriental Hospital. C5E is composed of ethanol 
extracts from a mixture of Ginseng, Chaga, 
Pinellia Tuber, Sparganium Rhizome, Alpinia 
Rhizome, Cinnamon Bark, Astragalus Root, 
Psoraleae Semen, Evodia Fruit, and Meliae 
Fructus. There have been several reports 
regarding these materials, but this study is the 
first to analyze the effect of these extracts on 
B16F10 melanoma cells [23-25]. In this study, 
the following effects of C5E ethanol extracts 
were examined: inhibition of the proliferation of 
B16F10 and keratinocyte cells, apoptotic 
signaling pathway in B16F10 cells, induction of 
cell cycle arrest in B16F10 cells, and inhibition of 
the proliferation of B16F10 cells when combined 
with vinblastine. C5E dose-dependently inhibited 
the proliferation of the melanoma cell lines in this 
study. C5E at 800 µg/mL, the maximal inhibitory 
dose in terms of cell proliferation, effectively 
suppressed the proliferation of B16F10 cells (77 
% inhibition of proliferation) and keratinocytes 
(36 % inhibition of proliferation). To further 
investigate this finding, a time-course analysis 
was conducted with B16F10, A375, 
keratinocytes, and NCI-H1299 cells incubated in 
the presence or absence of vinblastine (55 nM) 
at 24 and 48 h. The results showed that C5E had 
clearly continuous inhibitory effects in contrast to 
the control at 24 h. The data showed that C5E 
has dose- and time-dependent inhibitory effects 
on the proliferation of both melanoma cell lines 
(Figures 2C and 2D). 
 
Apoptosis is an important function for maintaining 
body systems because dysfunction of apoptotic 
signaling could cause serious conditions such as 
cancer and autoimmune disease [26]. Apoptosis 
is normally induced by the sequential activation 
of caspases, leading to cell death. Caspases are 
normally present in an inactive procaspase form 
but exist as a cleaved form when triggered. The 
extrinsic pathway of apoptosis involves the 
activation of caspase 8, which can directly cause 
the activation of downstream caspases such as 
caspases-3, -6, and -7 [27]. The intrinsic pathway 
controls mitochondria-dependent apoptosis, 
which leads to the activation of caspase 9 
through apoptotic protease activating factor-1 
(APAF-1) and cytochrome c release [28]. The 
cleavage of bid to tbid is induced by caspase 8 
through the death receptor pathway of apoptosis 
and it mediates mitochondrial apoptosis [29,30]. 
In order to understand the cause of cytotoxic 
effects induced by C5E in B16F10 melanoma, 
we investigated apoptotic signaling using 
western blot analyses and immunohisto-
chemistry.  
 
Induction of apoptosis in B16F10 cells was 
determined by flow cytometry-based-annexin V 
staining. C5E from 200 and 400 µg/ml enhanced 
the percentage of apoptotic melanoma cells 
(Figures 3A and 3B). The present data show that 
C5E can induce the apoptosis of B16F10 cells 
through the activation of caspases-3, -7, Bax, 
and PARP (Figure 3C, Figure 4), suggesting that 
C5E induces apoptosis through both of the major 
mechanisms, the extrinsic and the intrinsic 
pathway [6]. The inhibitory effects of C5E on cell 
proliferation were further studied by analyzing the 
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cell cycle. The cell cycle consists of 4 distinct 
phases, the G1, S, G2, and M phases. Each 
phase has a checkpoint that is regulated by 
many proteins. If a DNA mutation is detected, 
p53 blocks cell cycle progression and repairs the 
damaged DNA or induces apoptosis [31]. C5E 
(0.4 mg/ml) caused cell cycle arrest in the sub-
G1 phase in B16F10 melanoma cells (Figure 5) 
suggesting that C5E participated partly in the 
anti-proliferation of B16F10 cells via sub-G1 
phase arrest in addition to the apoptotic pathway. 
Cell cycle-related proteins, such as p53, p-p53, 
and CDK4, were activated.  
 
However, cyclins, which drive the cell cycle 
forward, were slightly down regulated (Figure 
5C). Although C5E showed weak cell cycle 
arresting effects in contrast to vinblastine, its 
extract effectively caused apoptosis in the late 
stages (Figure 3). NF-kB is generally inhibited by 
IkB, which is regulated by IKK. IKK 
phosphorylates IkB, which is subsequently 
degraded by the proteasome. Then, free NF-kB 
translocates to the nucleus and turns on cell 
survival-related genes [32]. Several reports 
revealed that inhibition of the NF-kB and 
PI3K/Akt signaling pathways can induce 
apoptosis in cancer cells [33,34]. The present 
results show that p-Akt/Akt as well as p-IkB 
levels were decreased by C5E and the maximal 
combined effect against p-Akt was caused with 
0.4 mg/mL C5E plus vinblastine (Figure 6B). 
 
It has been shown that the protein mTOR is 
phosphorylated in several lung cancer cell lines 
[35,36]. Importantly, mTOR activation was more 
frequent in tumors with gene alterations such as 
EGFR mutations or PI3K/Akt over-expression 
[37]. Phosphorylation of mTOR was decreased 
by C5E and a combined effect was caused by 
0.4 mg/ml C5E plus vinblastine (Figure 6C). 
These results suggest that C5E inhibits cell 
survival signals and interrupts cell proliferation by 





We have demonstrated that C5E can inhibit 
effectively the proliferation of B16F10 and A375 
melanoma cells via the induction of apoptotic 
signaling through both intrinsic and extrinsic 
pathways while inactivating the phosphorylation 
of Akt and IkB. This extract can also cause cell 
cycle arrest at the sub-G1 phase. The extract 
also showed a combined effect with vinblastine 
on the inhibition of cell proliferation, but it was not 
cytotoxic to normal cells, indicating that it may 
act effectively as an anti-cancer agent with 
minimal side effects. However, further studies 
are required to investigate the uses of this extract 
for pre-clinical development. 
 
Our results indicate that C5E has multiple effects 
in the induction of apoptosis and the inhibition of 
tumor survival and growth, and may be a useful 
complementary agent during vinblastine 
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